Antibodies, such as alirocumab,22 targeted against circulating PCSK9 are a novel class of lipid-lowering agents, which, in combination with or without statins, have been shown to successfully reduce blood cholesterol levels and the incidence of cardiovascular events, relative risk, and mortality of cardiovascular diseases.21, 22, 23, 24, 25 Recently, a number of studies investigated the pleiotropic effects of PCSK9 inhibitors beyond their lipid-lowering properties. Here, PCSK9 is linked to cardiovascular disorder.